Showing 1407 results
-
Press release /ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients[1] The Tasigna TFR trials, including ENESTop, demonstrate our continued…
-
Story /Novartis researcher Joana Silva had a life-changing experience with a mentor.
-
Press release /New x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on…
-
Press release /In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two…
-
Press release /CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, up to $400 million of shares of its…
-
Story /Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.
-
Press release /Cosentyx is the first and only IL-17A inhibitor from a new class of medicines shown to treat two of the most common inflammatory joint conditions in Europe[1] Cosentyx shows rapid and…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm,…